Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$17 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
P/E Ratio
5.7
P/B Ratio
1.8
Industry P/E
--
EV/EBITDA
-1.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
32,689,200
CFO
$-10,891.98 Mln
EBITDA
$-72.03 Mln
Net Profit
$-62.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ProMIS Neurosciences Inc (PMN)
| -47.2 | -21.3 | -44.4 | -72.9 | -53.0 | -40.1 | -- |
|
BSE Sensex*
| 4.5 | 4.1 | 7.7 | 10.5 | 15.7 | 22.1 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
ProMIS Neurosciences Inc (PMN)
| -17.5 | -73.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ProMIS Neurosciences Inc (PMN)
|
0.5 | 16.8 | 0.0 | -0.9 | -- | -11.2 | 5.7 | 1.8 |
| 2.3 | 3.6 | 0.7 | -10.3 | -1,278.2 | -203.6 | -- | 0.0 | |
| 145.0 | 10,989.7 | 12,968.5 | 859.6 | 15.0 | -- | 14.4 | 21.6 | |
| 121.2 | 12,183.3 | 5,512.6 | 494.7 | 17.0 | 16.3 | 24.9 | 5.6 | |
| 0.6 | 200.2 | 0.0 | -3.3 | -- | -- | -- | 0.0 | |
| 7.9 | 207.6 | 7.0 | -20.0 | -271.4 | -13.4 | -- | 1.4 | |
| 2.3 | 16.2 | 2.9 | -8.4 | -181.0 | -- | -- | 63.9 | |
| 1.3 | 208.8 | 41.6 | -202.0 | -496.2 | -136.3 | -- | 2.0 | |
| 147.7 | 8,609.5 | 4,423.4 | 309.4 | 9.2 | 16.8 | 28.3 | 4.5 | |
| 196.8 | 12,755.3 | 16,084.1 | 1,196.9 | 10.9 | 17.4 | 11.1 | 1.9 |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective... Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada. Read more
Co-Founder & Chairman
Mr. Eugene Williams
Co-Founder & Chairman
Mr. Eugene W. Williams
Headquarters
Toronto, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ProMIS Neurosciences Inc (PMN) stood at $ 18 Mln as on 31-Mar-25
The share price of ProMIS Neurosciences Inc (PMN) is $0.50 (NASDAQ) as of 19-May-2025 16:00 EDT. ProMIS Neurosciences Inc (PMN) has given a return of -53.01% in the last 3 years.
ProMIS Neurosciences Inc (PMN) has a market capitalisation of $ 17 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of ProMIS Neurosciences Inc (PMN) is 1.77 times as on 16-May-2025, a 45% discount to its peers’ median range of 3.23 times.
The P/E ratio of ProMIS Neurosciences Inc (PMN) is 5.71 times as on 16-May-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ProMIS Neurosciences Inc (PMN) and enter the required number of quantities and click on buy to purchase the shares of ProMIS Neurosciences Inc (PMN).
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
The CEO & director of Mr. Eugene Williams. is ProMIS Neurosciences Inc (PMN), and CFO & Sr. VP is Mr. Eugene W. Williams.
There is no promoter pledging in ProMIS Neurosciences Inc (PMN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
20
|
|
|
16
|
|
|
2
|
|
|
0
|
|
|
1,210
|
|
|
1,202
|
|
|
1,057
|
|
|
832
|
| ProMIS Neurosciences Inc. (PMN) | Ratios |
|---|---|
|
Return on equity(%)
|
-11.15
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ProMIS Neurosciences Inc (PMN) was $0 Mln.
$-0.01
(
